LinkedIn Profile

Access Nodality historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:nodality 404680 May 30th, 2019 12:00AM Nodality Inc. 524 2.00 Open Biotechnology May 30th, 2019 03:20PM May 30th, 2019 03:20PM Nodality is a San Francisco Bay Area life sciences company on a mission to help drug developers deliver more effective drugs to more precisely targeted patient groups. Our customers range from large pharmaceutical companies to small and mid-sized biotechnology companies. We provide high quality products and services to any drug developer with a compound whose performance could be improved. Nodality’s technology is founded around a multiparametric flow cytometry platform – Single Cell Network Profiling (SCNP) – that provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology at the single-cell level, creating competitive advantages in addressing many of the most pressing challenges in drug discovery and development. The use of SNCP provides our customers with network-level views of drug-to-target interactions in specific cells of interest including the identification of rare cell groups and cell subsets with potentially interesting or even compelling biological implications. We are able to deliver a rich package of clinically actionable information to our customers. We believe that revealing the activity, communication and change that occurs in individual cells and whole cellular networks will facilitate development of drugs from the preclinical stage all the way to the clinic. Nodality has a highly experienced management team hailing from Genentech, Genomic Health, Merck, Novartis, Onyx and Sugen. Founded in 2006 with technology licensed from Stanford University, the Company currently has an IP portfolio consisting of 20 issued patents and more than 100 patent applications. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp. Open Open 170 Harbor Way, Suite 200 South San Francisco CA US 94080 Nodality Pharmaceuticals & Biotechnology
private:nodality 404680 Mar 23rd, 2018 12:00AM Nodality Inc. 512 4.00 Open Biotechnology Mar 23rd, 2017 10:51AM Mar 23rd, 2017 10:51AM Nodality is a San Francisco Bay Area life sciences company on a mission to help drug developers deliver more effective drugs to more precisely targeted patient groups. Our customers range from large pharmaceutical companies to small and mid-sized biotechnology companies. We provide high quality products and services to any drug developer with a compound whose performance could be improved. Nodality’s technology is founded around a multiparametric flow cytometry platform – Single Cell Network Profiling (SCNP) – that provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology at the single-cell level, creating competitive advantages in addressing many of the most pressing challenges in drug discovery and development. The use of SNCP provides our customers with network-level views of drug-to-target interactions in specific cells of interest including the identification of rare cell groups and cell subsets with potentially interesting or even compelling biological implications. We are able to deliver a rich package of clinically actionable information to our customers. We believe that revealing the activity, communication and change that occurs in individual cells and whole cellular networks will facilitate development of drugs from the preclinical stage all the way to the clinic. Nodality has a highly experienced management team hailing from Genentech, Genomic Health, Merck, Novartis, Onyx and Sugen. Founded in 2006 with technology licensed from Stanford University, the Company currently has an IP portfolio consisting of 20 issued patents and more than 100 patent applications. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp. Nodality Pharmaceuticals & Biotechnology
private:nodality 404680 Feb 17th, 2018 12:00AM Nodality Inc. 512 4.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Nodality is a San Francisco Bay Area life sciences company on a mission to help drug developers deliver more effective drugs to more precisely targeted patient groups. Our customers range from large pharmaceutical companies to small and mid-sized biotechnology companies. We provide high quality products and services to any drug developer with a compound whose performance could be improved. Nodality’s technology is founded around a multiparametric flow cytometry platform – Single Cell Network Profiling (SCNP) – that provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology at the single-cell level, creating competitive advantages in addressing many of the most pressing challenges in drug discovery and development. The use of SNCP provides our customers with network-level views of drug-to-target interactions in specific cells of interest including the identification of rare cell groups and cell subsets with potentially interesting or even compelling biological implications. We are able to deliver a rich package of clinically actionable information to our customers. We believe that revealing the activity, communication and change that occurs in individual cells and whole cellular networks will facilitate development of drugs from the preclinical stage all the way to the clinic. Nodality has a highly experienced management team hailing from Genentech, Genomic Health, Merck, Novartis, Onyx and Sugen. Founded in 2006 with technology licensed from Stanford University, the Company currently has an IP portfolio consisting of 20 issued patents and more than 100 patent applications. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp. Nodality Pharmaceuticals & Biotechnology
private:nodality 404680 Feb 16th, 2018 12:00AM Nodality Inc. 512 4.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Nodality is a San Francisco Bay Area life sciences company on a mission to help drug developers deliver more effective drugs to more precisely targeted patient groups. Our customers range from large pharmaceutical companies to small and mid-sized biotechnology companies. We provide high quality products and services to any drug developer with a compound whose performance could be improved. Nodality’s technology is founded around a multiparametric flow cytometry platform – Single Cell Network Profiling (SCNP) – that provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology at the single-cell level, creating competitive advantages in addressing many of the most pressing challenges in drug discovery and development. The use of SNCP provides our customers with network-level views of drug-to-target interactions in specific cells of interest including the identification of rare cell groups and cell subsets with potentially interesting or even compelling biological implications. We are able to deliver a rich package of clinically actionable information to our customers. We believe that revealing the activity, communication and change that occurs in individual cells and whole cellular networks will facilitate development of drugs from the preclinical stage all the way to the clinic. Nodality has a highly experienced management team hailing from Genentech, Genomic Health, Merck, Novartis, Onyx and Sugen. Founded in 2006 with technology licensed from Stanford University, the Company currently has an IP portfolio consisting of 20 issued patents and more than 100 patent applications. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp. Nodality Pharmaceuticals & Biotechnology
private:nodality 404680 Feb 15th, 2018 12:00AM Nodality Inc. 512 4.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Nodality is a San Francisco Bay Area life sciences company on a mission to help drug developers deliver more effective drugs to more precisely targeted patient groups. Our customers range from large pharmaceutical companies to small and mid-sized biotechnology companies. We provide high quality products and services to any drug developer with a compound whose performance could be improved. Nodality’s technology is founded around a multiparametric flow cytometry platform – Single Cell Network Profiling (SCNP) – that provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology at the single-cell level, creating competitive advantages in addressing many of the most pressing challenges in drug discovery and development. The use of SNCP provides our customers with network-level views of drug-to-target interactions in specific cells of interest including the identification of rare cell groups and cell subsets with potentially interesting or even compelling biological implications. We are able to deliver a rich package of clinically actionable information to our customers. We believe that revealing the activity, communication and change that occurs in individual cells and whole cellular networks will facilitate development of drugs from the preclinical stage all the way to the clinic. Nodality has a highly experienced management team hailing from Genentech, Genomic Health, Merck, Novartis, Onyx and Sugen. Founded in 2006 with technology licensed from Stanford University, the Company currently has an IP portfolio consisting of 20 issued patents and more than 100 patent applications. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp. Nodality Pharmaceuticals & Biotechnology
private:nodality 404680 Feb 14th, 2018 12:00AM Nodality Inc. 512 4.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Nodality is a San Francisco Bay Area life sciences company on a mission to help drug developers deliver more effective drugs to more precisely targeted patient groups. Our customers range from large pharmaceutical companies to small and mid-sized biotechnology companies. We provide high quality products and services to any drug developer with a compound whose performance could be improved. Nodality’s technology is founded around a multiparametric flow cytometry platform – Single Cell Network Profiling (SCNP) – that provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology at the single-cell level, creating competitive advantages in addressing many of the most pressing challenges in drug discovery and development. The use of SNCP provides our customers with network-level views of drug-to-target interactions in specific cells of interest including the identification of rare cell groups and cell subsets with potentially interesting or even compelling biological implications. We are able to deliver a rich package of clinically actionable information to our customers. We believe that revealing the activity, communication and change that occurs in individual cells and whole cellular networks will facilitate development of drugs from the preclinical stage all the way to the clinic. Nodality has a highly experienced management team hailing from Genentech, Genomic Health, Merck, Novartis, Onyx and Sugen. Founded in 2006 with technology licensed from Stanford University, the Company currently has an IP portfolio consisting of 20 issued patents and more than 100 patent applications. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp. Nodality Pharmaceuticals & Biotechnology
private:nodality 404680 Feb 13th, 2018 12:00AM Nodality Inc. 512 4.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Nodality is a San Francisco Bay Area life sciences company on a mission to help drug developers deliver more effective drugs to more precisely targeted patient groups. Our customers range from large pharmaceutical companies to small and mid-sized biotechnology companies. We provide high quality products and services to any drug developer with a compound whose performance could be improved. Nodality’s technology is founded around a multiparametric flow cytometry platform – Single Cell Network Profiling (SCNP) – that provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology at the single-cell level, creating competitive advantages in addressing many of the most pressing challenges in drug discovery and development. The use of SNCP provides our customers with network-level views of drug-to-target interactions in specific cells of interest including the identification of rare cell groups and cell subsets with potentially interesting or even compelling biological implications. We are able to deliver a rich package of clinically actionable information to our customers. We believe that revealing the activity, communication and change that occurs in individual cells and whole cellular networks will facilitate development of drugs from the preclinical stage all the way to the clinic. Nodality has a highly experienced management team hailing from Genentech, Genomic Health, Merck, Novartis, Onyx and Sugen. Founded in 2006 with technology licensed from Stanford University, the Company currently has an IP portfolio consisting of 20 issued patents and more than 100 patent applications. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp. Nodality Pharmaceuticals & Biotechnology
private:nodality 404680 Feb 12th, 2018 12:00AM Nodality Inc. 512 4.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Nodality is a San Francisco Bay Area life sciences company on a mission to help drug developers deliver more effective drugs to more precisely targeted patient groups. Our customers range from large pharmaceutical companies to small and mid-sized biotechnology companies. We provide high quality products and services to any drug developer with a compound whose performance could be improved. Nodality’s technology is founded around a multiparametric flow cytometry platform – Single Cell Network Profiling (SCNP) – that provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology at the single-cell level, creating competitive advantages in addressing many of the most pressing challenges in drug discovery and development. The use of SNCP provides our customers with network-level views of drug-to-target interactions in specific cells of interest including the identification of rare cell groups and cell subsets with potentially interesting or even compelling biological implications. We are able to deliver a rich package of clinically actionable information to our customers. We believe that revealing the activity, communication and change that occurs in individual cells and whole cellular networks will facilitate development of drugs from the preclinical stage all the way to the clinic. Nodality has a highly experienced management team hailing from Genentech, Genomic Health, Merck, Novartis, Onyx and Sugen. Founded in 2006 with technology licensed from Stanford University, the Company currently has an IP portfolio consisting of 20 issued patents and more than 100 patent applications. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp. Nodality Pharmaceuticals & Biotechnology
private:nodality 404680 Feb 11th, 2018 12:00AM Nodality Inc. 512 4.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Nodality is a San Francisco Bay Area life sciences company on a mission to help drug developers deliver more effective drugs to more precisely targeted patient groups. Our customers range from large pharmaceutical companies to small and mid-sized biotechnology companies. We provide high quality products and services to any drug developer with a compound whose performance could be improved. Nodality’s technology is founded around a multiparametric flow cytometry platform – Single Cell Network Profiling (SCNP) – that provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology at the single-cell level, creating competitive advantages in addressing many of the most pressing challenges in drug discovery and development. The use of SNCP provides our customers with network-level views of drug-to-target interactions in specific cells of interest including the identification of rare cell groups and cell subsets with potentially interesting or even compelling biological implications. We are able to deliver a rich package of clinically actionable information to our customers. We believe that revealing the activity, communication and change that occurs in individual cells and whole cellular networks will facilitate development of drugs from the preclinical stage all the way to the clinic. Nodality has a highly experienced management team hailing from Genentech, Genomic Health, Merck, Novartis, Onyx and Sugen. Founded in 2006 with technology licensed from Stanford University, the Company currently has an IP portfolio consisting of 20 issued patents and more than 100 patent applications. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp. Nodality Pharmaceuticals & Biotechnology
private:nodality 404680 Feb 10th, 2018 12:00AM Nodality Inc. 512 4.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Nodality is a San Francisco Bay Area life sciences company on a mission to help drug developers deliver more effective drugs to more precisely targeted patient groups. Our customers range from large pharmaceutical companies to small and mid-sized biotechnology companies. We provide high quality products and services to any drug developer with a compound whose performance could be improved. Nodality’s technology is founded around a multiparametric flow cytometry platform – Single Cell Network Profiling (SCNP) – that provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology at the single-cell level, creating competitive advantages in addressing many of the most pressing challenges in drug discovery and development. The use of SNCP provides our customers with network-level views of drug-to-target interactions in specific cells of interest including the identification of rare cell groups and cell subsets with potentially interesting or even compelling biological implications. We are able to deliver a rich package of clinically actionable information to our customers. We believe that revealing the activity, communication and change that occurs in individual cells and whole cellular networks will facilitate development of drugs from the preclinical stage all the way to the clinic. Nodality has a highly experienced management team hailing from Genentech, Genomic Health, Merck, Novartis, Onyx and Sugen. Founded in 2006 with technology licensed from Stanford University, the Company currently has an IP portfolio consisting of 20 issued patents and more than 100 patent applications. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp. Nodality Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.